Wall Street analyst estimates for GRI Bio, Inc. (GRI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 1.10 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $100000 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $612 | $735 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$612 | -$735 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $3.5M | $1.9M | $264000 | $249000 | $242000 | $3.2M | $3.8M | $6.8M |
| Selling, General & Admin | $800076 | $1.3M | $1.2M | $813000 | $2.0M | $8.2M | $4.5M | $5.2M |
| Operating Expenses | $4.3M | $3.2M | $1.5M | $1.1M | $2.2M | $11.4M | $8.2M | $12.0M |
| Operating Income | -$4.3M | -$3.2M | -$1.5M | -$1.1M | -$2.2M | -$11.4M | -$8.2M | -$12.0M |
| EBITDA | -$4.3M | -$3.3M | -$1.5M | -$1.1M | -$2.6M | -$11.0M | -$8.2M | -$12.0M |
| Interest Expense | 0 | $197026 | $34000 | $547000 | $653000 | $2.1M | 0 | 0 |
| Pre-tax Income | -$4.3M | -$3.5M | -$2.5M | -$1.6M | -$3.2M | -$13.0M | -$8.2M | -$12.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$4.3M | -$3.5M | -$2.5M | -$1.6M | -$3.2M | -$13.0M | -$8.2M | -$12.0M |
| EPS | $-822780.00 | $-660968.00 | $-4693.64 | $-2827.16 | $-47135.48 | $-140450.24 | $0.33 | $-121.80 |
| EPS (Diluted) | $-822780.00 | $-660968.00 | $-4693.64 | $-2827.16 | $-47135.48 | $-140450.24 | $0.33 | $-121.80 |
| Shares Outstanding (Diluted) | $891 | $891 | $891 | $11602 | $1160 | $1578 | $4.9M | $98162 |
Price
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABP · BDRX · CANF · CLDI · CNSP · GNPX · INM
Explore sector: Healthcare · Biotechnology
More sections of GRI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks